Continuous discovery. Faster decisions. Stronger margins. The next phase of MedTech commercial advantage starts inside agreements you already own.

The largest unclaimed margin pool in MedTech is not waiting in the next tender. It is already sitting inside your signed agreements.

Research from World Commerce & Contracting puts the average post-signature value leakage at 11% of contracted spend, and 15% or more in portfolios with complex supplier ecosystems, indexation rights, and high-dependency clauses. For a MedTech business with $500M of contracted spend, that translates into $55M–$75M evaporating every year. Most of it leaves through rights the organisation already owns but cannot surface, interpret or activate inside the window the contract defines.

That gap, between what your agreements entitle you to and what your commercial teams can actually execute against, is now the defining margin constraint in MedTech. And in 2026, the pressure on that gap is widening every quarter.

The pressure curve has changed. The contract model has not.

Tariffs have added an estimated $200M to $500M in annual cost exposure for the largest MedTech manufacturers, with 50–80% of components in U.S.-made devices imported and now subject to volatility. NHS England, the DHSC and NHS Supply Chain are jointly building a MedTech Commercial Strategy that will weight at least 60% of tender scoring on value, capping whole-life cost at 40%. GPO and IDN consolidation continues to compress buyer leverage. Pricing scrutiny is intensifying across every major market.

The contract base that manufacturers rely on to absorb, recover or reprice that cost was negotiated in a calmer environment. The rights are still there. The escalation triggers are still there. The renegotiation thresholds are still there.

The problem is that, in most organisations, the contract stack still behaves like an archive.

Stored. Searched when needed. Reviewed under pressure. Revisited only when something goes wrong.

That model was acceptable when input costs moved on annual cycles. It is not acceptable when cost shocks land monthly and decision windows close in days.

The old model: contracts as storage

For most MedTech organisations, contract management was optimised for control, not commercial speed. Documents are stored. Renewals are tracked on a calendar. Legal review fires only when triggered. Commercial, pricing and account teams operate on memory, regional spreadsheets, and tribal knowledge.

In that model, every margin-relevant question creates manual work:

• Which agreements contain price escalation rights, and on what trigger?
• Which clauses allow renegotiation after input-cost or FX movement?
• Which frameworks restrict price change, and which permit it under specific evidence?
• Which buyers require advance notice, and how many days?
• Which volume commitments are unmet?
• Which renewal windows are inside 90 days?
• Which obligations expose the business to service, supply or penalty risk?

Each of these can be answered. None of them can be answered fast enough. By the time the analysis is done, the commercial window has usually moved.

That is the leakage. And it is structural.

The new model: continuous discovery

The next contract operating model is built around continuous discovery, not search.

Instead of waiting for a human to query the contract stack, domain-trained AI continuously reads, classifies and monitors every agreement across the portfolio. It identifies the clauses, dates, obligations, risks and rights that matter to pricing, tendering, account management, finance and legal, and surfaces them before they become urgent.

A contract is no longer the static output of a negotiation. It becomes a live source of commercial intelligence, escalating the right exposures to the right team, with the right evidence, inside the window where action is still possible.

Continuous discovery means escalation clauses are not discovered three months after costs have moved. Renewal windows are not missed. Rebate structures are not interpreted inconsistently across markets. Tender commitments are not separated from live account strategy. Contractual risks are not left buried until they surface as disputes.

The system does not replace legal or commercial judgement. It gives those teams the visibility, and the time, to exercise it.

Faster decisions, because the clock is shorter

Commercial windows in MedTech are short and shrinking.

A price escalation clause may require notice within a defined period. A renegotiation right may depend on a specific evidence threshold. A tender framework may restrict how, when, and on what grounds price can move. A buyer conversation may require a structured case backed by data, contract language and live market context, assembled in days, not weeks.

If a team needs three weeks to locate the relevant clauses, interpret the position, and build the evidence pack, the conversation has already moved on. The buyer has resolved the issue another way. The cost has been absorbed. The window has closed.

A continuous contract operating model collapses that cycle. It surfaces the relevant clauses, groups contracts by exposure, highlights notice periods, identifies the evidence required, and produces structured action packs the commercial team can take into the room. In Vamstar deployments, AI applied to tender and contract workflows is compressing cycle times by 60–70%, lifting win rates by 15–20%, and delivering 10–15x ROI inside 12–18 months.

That changes the question leadership asks.

It used to be: “Do we have any rights here?”

It is now: “Which rights can we activate, where, by when, and with what commercial case?”

That is a different operating rhythm, and a different return on the same contract base.

Stronger margins, from rights you already own

Margin recovery in MedTech is rarely a story of negotiating something new. It is a story of activating something existing.

Most MedTech portfolios already contain a deep inventory of margin-protective mechanisms: price-adjustment formulas, CPI and PPI indexation, FX clauses, minimum-volume thresholds, service-charge triggers, change-control rights, renewal levers, audit rights, and termination-for-convenience economics. These instruments only protect margin if they are found, understood, and activated inside the window the contract itself defines.

A live contract operating model connects those rights to commercial execution.

Pricing teams gain a clearer view of where price movement is contractually permissible, and where it is not. Account teams know which buyer conversations are commercially supported and what evidence the contract requires. Finance sees, at portfolio level, where margin exposure can be challenged or recovered. Legal focuses on interpretation and risk, not document retrieval. Leadership gets a single view of contractual actionability across every market.

The output is not better contract administration. It is margin control.

What this means for MedTech in 2026

The commercial environment is hardening in every direction at once. Tenders are more evidence-heavy. Buyers are more consolidated. Procurement criteria are more value-led. Sustainability and ESG expectations are becoming auditable. Cost volatility is structural, not transient. Local market variation continues to widen.

In that environment, no MedTech business can afford to leave contract intelligence passive. The contract stack has to become a live operating layer that supports pricing, tendering, renewals, account planning, margin protection, and executive decision-making, every day, not every quarter.

That is the new contract operating model:

• Continuous discovery of rights, risks and obligations across the portfolio.
• Faster decisions across commercial, legal and finance, measured in days, not weeks.
• Stronger margins through earlier action and better evidence.

The Vamstar view

At Vamstar, we treat contracts as the most underused source of commercial intelligence in MedTech, and the highest-yield place to deploy domain-trained AI.

Polaris AI is our agentic platform, purpose-built for life sciences and MedTech commercial work. It reads tenders, contracts, pricing records and market signals the way a senior commercial professional reads them: line by line, clause by clause, in context. Polaris Clause Monitoring surfaces escalation clauses, maps trigger conditions, and produces buyer-ready execution packs, closing the gap between cost shock and commercial recovery. Customers running Polaris are seeing 7.5% margin uplift and a 92% improvement in data intelligence coverage, alongside a measurable step-change in the speed at which contractual rights translate into commercial outcomes.

Unlike generalist CLM platforms, Polaris is fine-tuned to MedTech workflows: tender frameworks, payer policies, hospital and GPO contracting language, ESG and value-based procurement criteria, regional buyer behaviour. It is not a horizontal contract repository with an AI overlay bolted on. It is the intelligence layer the next contract operating model requires, and the one a generalist tool cannot provide.

In the next phase of MedTech commercial strategy, contracts will not sit at the edge.

They will sit at the centre.

The medical supply chain runs on accurate product data. Every surgical instrument, consumable, and device that passes through a healthcare facility needs to be correctly named, coded, and classified before it can be sourced, tracked, billed, or restocked. When that data is wrong, the consequences range from procurement inefficiency and billing errors to patient safety failures.

Getting it right, consistently and at scale, has proved harder than it should be.

The Classification Problem in Healthcare Procurement

Medical product nomenclature sits at the intersection of several compounding difficulties.

The sheer diversity of medical supplies creates immediate complexity. Products range from commodity consumables to highly specified surgical devices, each with manufacturer-specific naming conventions, proprietary part numbers, and varying descriptions depending on the country or catalogue they appear in. There is no single universal standard that governs how products are named and coded across the global supply chain.

Layering onto this is continuous product evolution. Medical technology advances quickly. New variants, line extensions, and entirely new device categories emerge regularly, requiring classification systems to be updated before procurement teams can act on them accurately.

Several structural factors then amplify these difficulties further. Some products belong legitimately to more than one category, creating genuine ambiguity. Manual data entry introduces errors at scale, and the staff resource needed to maintain classification accuracy is considerable. Regulatory requirements differ by jurisdiction, meaning a product correctly coded in one market may require a different classification in another. And where legacy systems are still in use, interoperability with modern procurement platforms adds another layer of friction.

The downstream effects are significant. Research consistently shows that healthcare procurement operates at transaction costs substantially higher than comparable industries. Wasteful and inappropriate spending, whether from misclassified products, duplicated purchases, or failed inventory control, accounts for a material share of healthcare expenditure in high-income countries. The volume of medical PPE deemed unusable following the COVID-19 pandemic, documented in UK parliamentary committee findings as running to billions of pounds, illustrated what happens when supply chain data quality failures occur at speed and scale.

Why Standard AI Falls Short for Code Matching

Generative AI has made rapid progress in text summarisation, content generation, and question-answering tasks. For medical product classification, however, general-purpose large language models have a significant limitation: they generate plausible-sounding outputs even when the underlying data is absent or ambiguous. In a classification context, this produces incorrect code assignments, a well-documented pattern in AI systems that researchers refer to as hallucination.

For procurement and supply chain applications, hallucination is not a marginal risk. An incorrect GMDN code, UNSPSC classification, or product taxonomy entry can propagate through ordering, invoicing, and inventory systems, creating errors that are difficult to detect and expensive to correct. The precision requirements of medical product coding make this a domain where confidence scores and source traceability matter as much as the output itself.

Effective AI for medical classification therefore requires a different architecture: one grounded in structured, curated healthcare product data rather than general web-trained knowledge.

Knowledge Graphs as the Missing Layer

The approach that addresses these limitations combines natural language processing with a healthcare-specific knowledge graph. Rather than relying on a language model to infer the correct classification from its training data alone, a knowledge graph approach structures relationships between products, codes, standards, and categories explicitly — and continuously updates them as new products enter the market.

This enables several capabilities that general AI cannot reliably provide:

• Code-to-code matching across different classification systems, such as mapping between UNSPSC, GMDN, and local hospital catalogue codes, with traceable logic rather than probabilistic guesses.

• Product-to-product comparison at a granular level, making it possible to identify equivalent or substitute products across different manufacturers and naming conventions.

• Code-to-product assignment for new or unclassified items, drawing on structured product relationships rather than free-text inference.

• Product-to-evidence linkage, connecting product records to clinical or procurement evidence to support sourcing decisions and formulary management.

• Product-to-opportunity matching, aligning product catalogues with active tenders, contracts, or procurement frameworks where a supplier’s products are eligible.

These capabilities compound in value when applied at the scale of a multi-country healthcare procurement operation, where catalogue harmonisation, cross-border sourcing, and supplier rationalisation all depend on consistent, trustworthy product data.

Practical Applications in Healthcare Procurement

The commercial impact of accurate classification and AI-supported code matching is felt most directly in three areas.

Catalogue harmonisation. Hospitals, group purchasing organisations, and integrated health systems typically operate with fragmented product master data inherited from multiple systems and suppliers. An AI-assisted harmonisation process can identify duplicates, resolve naming inconsistencies, and align internal codes to recognised standards, reducing catalogue bloat and improving spend visibility.

Tendering and contracting. Procurement teams preparing or evaluating tenders need confidence that product specifications are accurately described and correctly classified. AI-supported nomenclature tools reduce the manual review burden and lower the risk of specification errors that delay or invalidate tender submissions.

Supplier and inventory management. Accurate product classification is the precondition for reliable inventory control, demand forecasting, and supplier performance tracking. When product data is inconsistent across systems, these processes degrade. Cleaning and maintaining that data with AI-assisted tools reduces the resource cost of manual reconciliation.

What Good Implementation Looks Like

Deploying AI for medical device classification is not a plug-and-play exercise. The quality of the knowledge graph underpinning the system determines the quality of its outputs. Organisations evaluating solutions should look for:

• A clearly described data sourcing methodology, including which classification standards, regulatory databases, and product catalogues the knowledge graph is built from.

• Explainability at the code level. Procurement teams need to understand why a particular classification was assigned, not just what it is, particularly where the assignment will be used in regulated billing or compliance contexts.

• Update cadence. A knowledge graph that is not regularly refreshed will degrade as new products enter the market and standards evolve.

• Integration capability with existing systems, including ERP platforms, e-procurement tools, and contract management systems, without requiring wholesale infrastructure replacement.

Frequently Asked Questions

What is medical device classification and why does it matter?

Medical device classification is the process of assigning standardised codes and categories to healthcare products. Accurate classification affects procurement efficiency, billing accuracy, inventory management, and regulatory compliance. Errors in classification propagate through supply chain systems and can affect patient safety.

Why do AI systems struggle with medical product code matching?

General-purpose AI models are trained on broad data and produce probabilistic outputs. In medical classification, where precision is required and incorrect codes have operational consequences, models without grounding in structured healthcare product data tend to assign plausible but incorrect codes — a limitation known as hallucination.

What is a healthcare knowledge graph?

A knowledge graph is a structured representation of relationships between entities, in this context between products, classification codes, standards, manufacturers, and evidence sources. Used in procurement AI, it provides a traceable, updateable foundation for code matching and product comparison that general language models cannot replicate.

How does AI support healthcare tendering and procurement?

AI tools can match supplier product catalogues to tender specifications, identify equivalent products across different naming conventions, flag classification inconsistencies, and automate the routine data-matching work that currently requires manual analyst effort.

What should procurement teams look for when evaluating AI classification tools?

Key criteria include data sourcing transparency, explainability of code assignments, update frequency, accuracy benchmarks on real procurement datasets, and integration compatibility with existing systems.

Conclusion

Accurate medical product classification is foundational infrastructure for every procurement, contracting, and supply chain function in healthcare. The barriers to getting it right at scale — diverse products, inconsistent standards, continuous product evolution, and the limits of manual processes — are not new. What is new is the availability of AI approaches that combine natural language processing with structured healthcare knowledge graphs to address these barriers systematically.

The organisations that build reliable product master data now will have a structural advantage in procurement efficiency, catalogue harmonisation, and tendering speed as healthcare systems continue to consolidate and digitise their supply chains.

There is a failure mode that runs through medtech transformation programmes with striking consistency. Organisations invest in platforms, commission implementations, and deploy analytics. Then, months later, the value that was promised remains stubbornly out of reach — not because the technology was wrong, but because it was never close enough to the business to make a real difference.

The gap between platform capability and operational impact is not a technology problem. It is an engineering proximity problem. And the organisations starting to close that gap are doing so by redesigning around a fundamentally different delivery model: forward-deployed engineering.

MedTech Has Outgrown Detached Delivery Models

For most of the last decade, the dominant logic in enterprise software was clean separation. Product teams built platforms. Implementation teams deployed them. Commercial teams used them. The assumption was that complexity could be abstracted away — that a well-configured system, handed over with training and documentation, would find its way into operational reality.

That model worked adequately when medtech organisations operated in relatively stable conditions: predictable pricing environments, manageable regulatory overhead, standardised procurement routes, and commercial workflows that were complicated but not deeply interdependent.

Those conditions no longer hold.

Today’s medtech manufacturers are navigating fragmented commercial operations across dozens of markets, each with distinct procurement structures, tender requirements, formulary processes, pricing constraints, and evidence expectations. They are managing product portfolios across hospital systems that evaluate on different criteria. They are responding to procurement bodies that have professionalised their evaluation processes and are demanding more structured, evidence-backed submissions than ever before. And they are doing all of this while absorbing relentless pricing pressure from payers, commissioners, and health technology assessment bodies.

In that environment, the idea that transformation can be delivered by a distant engineering team operating at arm’s length from the field is not just impractical. It is structurally incompatible with how medtech now operates.

What Forward-Deployed Engineering Actually Means

Forward-deployed engineering is not a staffing arrangement. It is not outsourced development, traditional professional services, or solutions consulting with a rebranded title. Those models all share the same underlying assumption: that engineering and business operations are separate domains that interact at defined handoff points.

Forward-deployed engineering inverts that assumption.

In the FDE model, engineers work in close, sustained proximity to the users, workflows, and decision-makers they are building for. They operate inside the operating environment rather than adjacent to it. They understand the business logic not as a requirements document but as a lived daily reality — the pricing exception that always comes up in tender responses, the regulatory classification that changes how a product gets positioned in a particular market, the internal approval chain that determines whether a contract can be countersigned in time.

The result is a delivery model where technical capability is embedded directly into commercial and operational execution, rather than deployed from a distance and left to find purchase on its own.

This distinction matters enormously in medtech, where the distance between how a system is designed and how it is actually used in the field is often wide — and where that distance is where transformation value goes to die.

Why MedTech Is Especially Suited to This Model

Several structural features of medtech make forward-deployed engineering not just useful but increasingly necessary.

Operational fragmentation at scale. Medtech manufacturers rarely operate as monolithic commercial organisations. They run across countries, channels, distributor models, and product categories — each with its own operational logic. A remote engineering team modelling this complexity from the outside will, almost inevitably, miss the nuance that determines whether a system actually gets used. Engineers working inside specific commercial environments can see what generic platform logic cannot capture.

The procurement-commercial convergence. In medtech, procurement is no longer a downstream administrative function that follows commercial decisions. It has become a primary domain of commercial intelligence, operational risk, and competitive signal. Tender structures, contract requirements, value documentation standards, product eligibility criteria, and regulatory evidence expectations now directly shape how organisations price, respond, qualify, and scale. Engineering teams that sit apart from procurement-facing workflows are missing the domain where much of the highest-value complexity actually lives.

AI requires contextual proximity, not just data. The promise of AI in medtech is real, but it cannot be realised through deployment alone. AI systems — whether they are supporting tender response, pricing optimisation, contract analysis, or market access decisions — need to understand local naming inconsistencies, evidence hierarchies, procurement logic, approval chains, and workflow exceptions. That understanding does not come from a data schema. It comes from engineering judgement developed in close contact with real operational environments. Without embedded proximity, AI programmes in medtech tend to produce analytically interesting outputs that never quite connect to the decisions people actually need to make.

Transformation is now workflow-deep. The highest-value use cases in medtech are no longer about dashboard visibility. They are about orchestrating execution: helping commercial teams identify and qualify opportunities faster, ensuring pricing decisions are informed by contract obligations and tender constraints, accelerating the assembly of compliant and competitive responses, and creating the feedback loops that allow organisations to learn from the field in near-real time. That level of transformation requires engineers who understand workflows from the inside — not just the data that flows through them.

The Organisational Argument

Forward-deployed engineering is not only a delivery methodology. It implies, and often requires, an organisational shift in how medtech manufacturers structure the relationship between engineering, commercial, and operational teams.

Three realities are driving this restructuring in the most advanced organisations.

Engineering must sit closer to revenue-critical workflows. Tenders, contracts, pricing, market access, and evidence operations are not peripheral processes. They are often the primary mechanisms through which commercial value is won, protected, or lost. Engineering capability that can help model, automate, and accelerate those workflows is not a support function. It is a strategic asset that belongs close to where revenue decisions are made.

Procurement, commercial, and engineering teams need shared operating visibility. A consistent failure pattern in medtech transformation is the gap between systems ownership and business ownership. Engineering teams own the platform; commercial teams own the outcome; procurement teams own the process. In practice, execution failures live in the handoffs between those domains. Shared operating visibility — where engineers, commercial leaders, procurement stakeholders, and domain specialists are working in the same operational loop — substantially reduces the risk of transformation value falling into those gaps.

The best transformation teams are cross-functional by design. The older model placed product on one side of a boundary and users on the other, with implementation teams managing the crossing. In the FDE model, that boundary dissolves. Engineers, commercial operators, data owners, and domain specialists function as a single team oriented around specific operational outcomes. That is a meaningful organisational change, not just a delivery preference — and the organisations making it are finding that it dramatically shortens the time between capability and impact.

What Leading Manufacturers Are Doing Differently

Across the industry, a pattern is emerging among medtech organisations that are making serious progress on AI and data transformation programmes. They are not necessarily using better technology than their peers. They are using it differently — and structuring their delivery capacity to match the operational reality they are working in.

Specifically, they are embedding engineers into domain-specific transformation teams rather than keeping them in central product functions disconnected from field realities. They are prioritising workflow redesign over isolated tool deployment, recognising that changing what a team can do matters more than giving them a new dashboard. They are creating tighter feedback loops between field teams and platform teams, so that what is learned in live commercial execution informs what gets built and configured. And they are aligning engineering effort directly to measurable business outcomes — response rates, pricing accuracy, qualification speed, contract cycle time — rather than to platform capability milestones.

The effect is that transformation programmes in these organisations feel different from the inside. They move faster, encounter fewer adoption barriers, and produce results that are visible to the commercial teams who have to live with them. That is not coincidental. It is the product of engineering proximity.

Why This Is Where AI Becomes Operationally Useful

This is also why the broader conversation about AI in medtech needs to shift from deployment to operationalisation.

Platforms do not create impact in isolation. Impact comes from the combination of domain-tuned technology, high-quality data integration, genuine workflow understanding, and embedded engineering execution. Without all four, AI investments tend to plateau at analytical interest — producing outputs that are technically impressive but commercially inert.

Vamstar’s forward-deployed engineering model is designed to close precisely this gap. By embedding engineering capability directly into the commercial and procurement environments where clients operate, Vamstar helps organisations translate Polaris’s platform capabilities into live operational workflows — across tenders, pricing, contracts, and market access — rather than leaving value trapped at the platform level. The result is AI that does not just produce insight but shapes the decisions and actions that determine commercial outcomes.

The New Operating Standard

Forward-deployed engineering is not a niche delivery variant for organisations with unusual complexity. In medtech, it is increasingly the operating model required to make transformation programmes work.

The failure mode was never lack of software. It was the distance between technical capability and operational reality. As medtech commercial and procurement environments grow more complex — more data-intensive, more market-specific, more tightly interdependent — that distance becomes increasingly costly.

The organisations that will lead the next phase of medtech transformation are those that recognise this, and that build or access the embedded engineering capability needed to close the gap. Not by deploying better tools from further away, but by bringing technical judgement into direct contact with the complexity that defines how modern medtech actually operates.

That is what the rise of forward-deployed engineering means in practice. And it is why, for serious transformation programmes in medtech, it is no longer optional infrastructure. It is the model.

Diabetes has escalated into a major global health crisis, with the International Diabetes Federation (IDF) forecasting a staggering 643 million cases by 2030 and 783 million by 2045. As the World Health Organization (WHO) labels diabetes a global epidemic, the urgency to address its impact intensifies. In Europe alone, the chronic disease affects around 60 million adults, equivalent to one in eleven individuals, underscoring its status as a pressing public health concern.

A Rich History of Treatment and a Promising Future

Diabetes management has evolved dramatically over the years, from traditional insulin injections and diet modifications to cutting-edge wearable continuous glucose monitors (CGMs) and insulin pumps. Countries like Germany, the UK, and France lead the charge in the European anti-diabetic drug market, driven by an aging population and increasing disease prevalence. Yet, the quest for more effective and natural treatment options continues.

For years, MedTech leaders could treat geopolitics, trade policy, procurement reform, cybersecurity, and regulatory disruption as adjacent pressures: important, certainly, but not always commercially decisive.

That distinction is disappearing.

Today, the MedTech operating landscape is being reshaped by the stacking effect of multiple external pressures arriving at once. Demand remains. Clinical need remains. Innovation remains. But the route to revenue is becoming slower, more fragmented, and more exposed to political and operational volatility. What once sat at the edge of commercial planning now bears directly on margin, tender performance, contract velocity, and market access execution.

This is the emerging reality for MedTech. The winners will not simply be the firms with the strongest products. They will be the ones that can absorb geopolitical shocks, reprice quickly, prove value clearly, and execute tenders and contracts with far less friction.

The market is not weakening. The operating environment is hardening

That distinction matters.

The challenge facing MedTech is not a collapse in healthcare demand. In many categories, demand remains structurally strong. Hospitals still need equipment, consumables, diagnostics, digital tools, and service support. Health systems still face rising demand, ageing populations, workforce shortages, and relentless pressure to improve outcomes.

What is changing is the degree of difficulty involved in turning capability into revenue.

The commercial path is increasingly obstructed by external variables that are harder to predict and harder to control. Tariff exposure can alter cost positions with little warning. Procurement frameworks are becoming more politically shaped. Regulatory obligations continue to consume internal resources. Cybersecurity has moved from technical hygiene to commercial credibility. Regional instability threatens logistics, freight economics, energy costs, and supply continuity.

None of these pressures is entirely new on its own. The problem is their convergence.

MedTech companies are no longer dealing with isolated disruptions. They are operating in an environment where cost, compliance, access, and execution risk reinforce one another.

Margin pressure is becoming structural

One of the clearest implications of this landscape is that margin pressure is becoming harder to manage through traditional means alone.

In the past, cost inflation could often be framed as a sourcing problem, a productivity issue, or a pricing discussion. Today, it is more complicated. Cost volatility is increasingly shaped by forces beyond the direct control of commercial and operations teams. Trade disputes, tariff shifts, shipping risk, raw-material exposure, energy costs, and regional instability can all alter the economics of a product line quickly.

That would be difficult enough on its own. But MedTech companies rarely operate in markets where pricing can be changed cleanly or instantly. Contracts are often fixed. Tender cycles are rigid. Public buyers are under financial pressure. Evidence expectations are rising. In some markets, even when cost pressure is obvious, price movement remains commercially and politically difficult.

The result is a dangerous squeeze. Costs can move faster than pricing. Margin leakage appears not only through manufacturing or logistics, but through delayed repricing, poor contract visibility, inconsistent exception handling, and weak alignment between local teams and central strategy.

This is why repricing speed is becoming a strategic capability rather than a finance exercise. Firms that cannot see where they are exposed, assess what can be moved, and act with confidence will find themselves absorbing shocks for too long.